Screening for Prognostic microRNAs Associated with Treatment Failure in Diffuse Large B Cell Lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP yields 5-year survival rates of 60-70%.
• A significant portion of DLBCL patients (30-40%) experience poor long-term outcomes despite standard therapy.
• Identifying prognostic biomarkers is crucial for early detection of treatment failure in DLBCL.

Purpose of the Study:

• To discover novel prognostic biomarkers for early identification of diffuse large B cell lymphoma (DLBCL) patients with poor long-term prognosis.
• To validate the efficacy of identified microRNAs (miRNAs) as predictive markers for DLBCL treatment response.
• To elucidate the functional role of candidate miRNAs in DLBCL chemoresistance and cell cycle control.

Main Methods:

• A novel strategy involving microarray analysis of miRNA expression in DLBCL patient cohorts.
• Discovery cohort: 12 DLBCL patients (chemoresistant vs. chemosensitive).
• Validation cohort: 68 DLBCL patients to confirm miRNA impact on survival.

Main Results:

• Three microRNAs (miRNAs) were identified as significant prognostic markers impacting event-free and overall survival in DLBCL.
• miR-1244 and miR-193b-5p demonstrated functional roles in cell cycle control and chemoresistance pathways.
• miR-1231 was implicated in immunological processes, suggesting distinct roles in DLBCL pathogenesis.

Conclusions:

• A novel strategy successfully identified three miRNAs as promising prognostic markers for DLBCL.
• These biomarkers can aid in stratifying DLBCL patients at high risk of treatment failure with standard therapy.
• The findings offer potential for improved personalized treatment strategies in DLBCL management.